At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MRNY YieldMax MRNA Option Income Strategy ETF
Not Yet Opened 03-03 16:00:00 EST
19.11
-0.91
-4.55%
盘后19.95
+0.84+4.40%
19:57 EST
High19.63Low18.45Vol405.36K
Open19.24D1 Closing20.02Amplitude5.89%
Mkt Cap95.65MTradable Cap93.73MTotal Shares5.00M
T/O7.72MT/O Rate8.26%Tradable Shares4.90M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Moderna Agrees to Pay up to $2.25 Billion to Settle COVID Vaccine Patent Dispute
Reuters  ·  06:52
Moderna Agrees to Pay up to $2.25 Billion to Settle COVID Vaccine Patent Dispute
Patent Dispute Resolution Paves Way for Moderna's AI-Driven Healthcare Push
Stock News  ·  08:56
Patent Dispute Resolution Paves Way for Moderna's AI-Driven Healthcare Push
Stocks to Watch: Moderna, Ross Stores, Latham, Webtoon
Dow Jones  ·  07:44
Stocks to Watch: Moderna, Ross Stores, Latham, Webtoon
Moderna: Litigation Relief Supports Oncology Pipeline, But Legal Overhang Keeps Risk‑Reward Balanced at Hold
TIPRANKS  ·  07:35
Moderna: Litigation Relief Supports Oncology Pipeline, But Legal Overhang Keeps Risk‑Reward Balanced at Hold
Moderna Chief Legal Officer Shannon Thyme Klinger Disposes of Common Shares
Reuters  ·  06:06
Moderna Chief Legal Officer Shannon Thyme Klinger Disposes of Common Shares
Moderna Stock Jumps 10% After Hours: Here's Why
Benzinga  ·  05:55
Moderna Stock Jumps 10% After Hours: Here's Why
Shares of Moderna up 10% in Extended Trade; Co Agrees to Payment to Settle Vaccine Dispute
THOMSON REUTERS  ·  05:52
Shares of Moderna up 10% in Extended Trade; Co Agrees to Payment to Settle Vaccine Dispute
Moderna Inc. Stock Slips 5.7%, Underperforms Peers
Dow Jones  ·  05:34
Moderna Inc. Stock Slips 5.7%, Underperforms Peers
BRIEF-Moderna 2026 Year-End Cash And Cash Equivalents Now Expected To Be In The Range Of $4.5 Billion-$5 Billion
Reuters  ·  05:25
BRIEF-Moderna 2026 Year-End Cash And Cash Equivalents Now Expected To Be In The Range Of $4.5 Billion-$5 Billion
Moderna - in 2026, to Return to REV Growth & End Year With More Than $5 Bln in Liquidity, as We Drive Toward Breakeven in 2028
THOMSON REUTERS  ·  05:18
Moderna - in 2026, to Return to REV Growth & End Year With More Than $5 Bln in Liquidity, as We Drive Toward Breakeven in 2028
Moderna - Expects to Record a Charge of $950 Million in First Quarter of 2026 Related to Settlement Payment
THOMSON REUTERS  ·  05:18
Moderna - Expects to Record a Charge of $950 Million in First Quarter of 2026 Related to Settlement Payment
Moderna - Total Projected Liquidity Available to Co at End of 2026 Will Be $5.4 to $5.9 Billion
THOMSON REUTERS  ·  05:18
Moderna - Total Projected Liquidity Available to Co at End of 2026 Will Be $5.4 to $5.9 Billion
Moderna: 2026 Year-End Cash and Cash Equivalents NOW Expected to Be in the Range of $4.5 - $5.0 Billion
THOMSON REUTERS  ·  05:18
Moderna: 2026 Year-End Cash and Cash Equivalents NOW Expected to Be in the Range of $4.5 - $5.0 Billion
Roivant Sciences: Under Settlement, Genevant to Give Moderna Non-Exclusive License to Lnp Delivery Technology for Infectious Disease Applications
THOMSON REUTERS  ·  05:15
Roivant Sciences: Under Settlement, Genevant to Give Moderna Non-Exclusive License to Lnp Delivery Technology for Infectious Disease Applications
Moderately bullish activity in Moderna with shares down 7.15%
TIPRANKS  ·  00:40
Moderately bullish activity in Moderna with shares down 7.15%
Should You Listen to Billionaires to Buy Moderna Stock in 2026?
TradingKey  ·  03-03 20:44
Should You Listen to Billionaires to Buy Moderna Stock in 2026?
MAHA Is Bringing Chaos to Biotech Investment Beyond Just Vaccines -- Heard on the Street -- WSJ
Dow Jones  ·  03-03 18:30
MAHA Is Bringing Chaos to Biotech Investment Beyond Just Vaccines -- Heard on the Street -- WSJ
Moderna Stock (MRNA): Is It a Buy Now? 7 Questions After the Crash
InvestorPlace  ·  03-03 05:28
Moderna Stock (MRNA): Is It a Buy Now? 7 Questions After the Crash
Correction to FDA Article on Feb. 11 -- WSJ
Dow Jones  ·  03-03 02:37
Correction to FDA Article on Feb. 11 -- WSJ
Rothschild & Co Redburn Adjusts Price Target on Moderna to $40 From $36, Maintains Neutral Rating
MT Newswires Live  ·  02-28
Rothschild & Co Redburn Adjusts Price Target on Moderna to $40 From $36, Maintains Neutral Rating

Introduction

Company Name.
YieldMax MRNA Option Income Strategy ETF
Affiliated Markets:
ARCA
Listing Date:
--
Main Business:
The fund advisor will seek to employ the fund's investment strategy as the fund relates to MRNA regardless of whether there are periods of adverse market, economic, or other conditions and will not seek to take temporary defensive positions during such periods. The fund is non-diversified.
Issue price:
--